tickrz reports
tickrz rank
D
Celgene Corp (CELG)
Healthcare | Drugs
136.71  0.18%
FACTOR RANKINGSFACTOR SCREENER 
tickrz RankD / 368Warren Buffett RankD / 393
Pure Value RankD / 469Dividend RankD / NO DIVIDEND
Moat RankA / 48Financial Strength RankA / 93
Growth RankA / 81Momentum RankA / 68
CELG vs DRUGS SECTOR & S&P 500
VALUATION
CELGSECTORS&P 500
P/E RATIO42.5735.919.61
EV/EBITDA RATIO29.7825.111.89
P/S RATIO9.0972.06
P/B RATIO13.128.73.15
QUALITY
RETURN ON EQUITY37.19%16.98%13.85%
RETURN ON CAPITAL25.82%26.23%10.02%
NET MARGIN18.3%14.46%9.77%
DIVIDEND ANALYSIS
DIVIDEND YIELD
0%
PAYOUT RATION/A
3 YR DIVIDEND GROWTHN/A
FINANCIAL STRENGTH
PIOTROSKI F SCORE
7 OUT OF 9
DEBT-TO-EQUITY169%
INTEREST COVERAGE5.54x
CURRENT RATIO4.05
GROWTH
5 YR EPS GROWTH11.81%
5 YR SPS GROWTH17.67%
5 YR BPS GROWTH6.11%
About tickrz
Key Concepts
Great Investors
Celgene Corp 's strong growth translates to a Growth Rank in the top 25% of all stocks
tickrz rank D / 368
Celgene Corp receives a D ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.
value
pure value ranking D / 469Warren Buffett ranking D / 393
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Celgene Corp's valuation score is comprised of a P/E ratio of 42.6x, a P/B ratio of 13.1x, a P/S ratio of 9.1x, and an EV/EBITDA ratio of 29.8x. Celgene Corp ranks 469 out of the S&P 500 constituents on valuation--a relatively weak score.Celgene Corp ranks 393 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a weak score, meaning it ranks poorly on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Celgene Corp is probably not for you. However, the company's moat is strong so it could be worth investigating in the future should its valuation improve.

quality
moat A / 48financial strength A / 93
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is strong. Celgene Corp appears to have a durable competitive advantage within the Healthcare sector. Celgene Corp has a Piotroski F Score of 7 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 5.54x, a debt/equity ratio of 169% and a Moat Rank of 48 translate to a strong Financial Strength score.


momentum A / 68
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors. The company has seen its stock appreciate by 40.38% over the last 12 months. This performance is strong compared to other stocks in the S&P 500, earning it a rank of 68. Celgene Corp's strong 12 month stock performance will appeal to momentum investors.

yield D / NO DIVIDEND
value + yield
Celgene Corp currently does not pay a dividend so it ranks last among S&P 500 companies using our dividend ranking methodology. Investors looking for undervalued dividend stocks will probably want to look elsewhere.

growth A / 81
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the top third of S&P 500 companies. Its 11.8% 5 year annualized EPS growth, 17.7% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of 6.1% speak to its impressive growth ranking.

Celgene Corp (CELG)
Healthcare | Drugs
136.71  0.18%


tickrz rank
D
VALUATION RATIOS
P/E Ratio42.57x
P/B Ratio13.12x
P/S Ratio9.09x
EV/EBITDA Ratio29.78x
DIVIDEND ANALYSIS
DIVIDEND YIELD
0%
PAYOUT RATION/A
3 YR DIVIDEND GROWTHN/A
FINANCIAL STRENGTH
PIOTROSKI F SCORE
7 OUT OF 9
DEBT-TO-EQUITY169%
INTEREST COVERAGE5.54x
CURRENT RATIO4.05
MOAT
ROE37.19%
ROIC25.82%
Net Margin18.3%
GROWTH
5 YR EPS GROWTH11.81%
5 YR SPS GROWTH17.67%
5 YR BPS GROWTH6.11%

TICKRZ RANK
Celgene Corp receives a D ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.

PURE VALUE
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Celgene Corp's valuation score is comprised of a P/E ratio of 42.6x, a P/B ratio of 13.1x, a P/S ratio of 9.1x, and an EV/EBITDA ratio of 29.8x. Celgene Corp ranks 469 out of the S&P 500 constituents on valuation--a relatively weak score.

WARREN BUFFETT RANKING
Celgene Corp ranks 393 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a weak score, meaning it ranks poorly on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Celgene Corp is probably not for you. However, the company's moat is strong so it could be worth investigating in the future should its valuation improve.

MOAT
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is strong. Celgene Corp appears to have a durable competitive advantage within the Healthcare sector.

FINANCIAL STRENGTH
Celgene Corp has a Piotroski F Score of 7 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 5.54x, a debt/equity ratio of 169% and a Moat Rank of 48 translate to a strong Financial Strength score.

MOMENTUM
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors. The company has seen its stock appreciate by 40.38% over the last 12 months. This performance is strong compared to other stocks in the S&P 500, earning it a rank of 68. Celgene Corp's strong 12 month stock performance will appeal to momentum investors.

VALUE + YIELD
Celgene Corp currently does not pay a dividend so it ranks last among S&P 500 companies using our dividend ranking methodology. Investors looking for undervalued dividend stocks will probably want to look elsewhere.

GROWTH
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the top third of S&P 500 companies. Its 11.8% 5 year annualized EPS growth, 17.7% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of 6.1% speak to its impressive growth ranking.